Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;17(12):1276-1284.
doi: 10.1016/S1473-3099(17)30541-8. Epub 2017 Oct 9.

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

Affiliations

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

Pierre-Stéphane Gsell et al. Lancet Infect Dis. 2017 Dec.

Erratum in

  • Corrections.
    [No authors listed] [No authors listed] Lancet Infect Dis. 2017 Dec;17(12):1232. doi: 10.1016/S1473-3099(17)30646-1. Epub 2017 Nov 8. Lancet Infect Dis. 2017. PMID: 29128514 Free PMC article. No abstract available.

Abstract

Background: In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.

Methods: Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities. Vaccination teams and frozen vaccine were flown to the outbreak settings. Rings of contacts and contacts of contacts were defined and eligible individuals, who had given informed consent, were vaccinated and followed up for 21 days under good clinical practice conditions.

Findings: Between March 17 and April 21, 2016, 1510 individuals were vaccinated in four rings in Guinea, including 303 individuals aged between 6 years and 17 years and 307 front-line workers. It took 10 days to vaccinate the first participant following the confirmation of the first case of Ebola virus disease. No secondary cases of Ebola virus disease occurred among the vaccinees. Adverse events following vaccination were reported in 47 (17%) 6-17 year olds (all mild) and 412 (36%) adults (individuals older than 18 years; 98% were mild). Children reported fewer arthralgia events than adults (one [<1%] of 303 children vs 81 [7%] of 1207 adults). No severe vaccine-related adverse events were reported.

Interpretation: The results show that a ring vaccination strategy can be rapidly and safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.

Funding: WHO, Gavi, and the World Food Programme.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Probable chain of transmission in Guinea, from February to April, 2016 (A) Chain of transmission. (B) Date of confirmed cases refers to date of an RT-PCR positive diagnosis. Reproduced from Diallo and colleagues, by permission of Oxford Journals. G=case in Guinea. L=case in Liberia. M=male case. F=female case. NA=not available. *Died. †Possible date of onset.
Figure 2
Figure 2
Map of west Africa and location of Nzérékoré prefecture The flight path indicates how the vaccination teams travelled from Conakry to Nzérékoré. The inset map indicates the location of the four rings defined by their index cases and their contacts and contacts of contacts, including those resident in satellite sites.
Figure 3
Figure 3
Timeline of operations in the four rings in Guinea

Comment in

References

    1. Henao-Restrepo AM, Longini IM, Egger M. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866. - PubMed
    1. WHO Liberia and Guinea discharge final Ebola patients in latest flare-up and begin 42 days of heightened surveillance. http://www.who.int/features/2016/ebola-patients-discharge/en/ (accessed Sept 22, 2017).
    1. Ebola ça Suffit Ring Vaccination Trial Consortium The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015;351:h3740. - PMC - PubMed
    1. WHO. CDC Implementation and management of contact tracing for Ebola virus disease. http://www.who.int/csr/resources/publications/ebola/contact-tracing/en/ (accessed Sept 22, 2017).
    1. Diallo B, Sissoko D, Loman NJ. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis. 2016;63:1353–1356. - PMC - PubMed

Publication types